THC Therapeutics, Inc. has announced the acquisition of The Headquarters Group, Inc. in an all-share transaction valued at approximately $11 million.
The deal was completed through the issuance of 11,007,000 shares of newly created Series D Preferred stock.
Founded in 2001, The Headquarters Group operates a portfolio of cannabis-related businesses across cultivation, extraction, distribution, genetics, real estate, and plant nutrients. As part of the acquisition, THC Therapeutics now owns 100% of THG and its subsidiaries, which collectively generated around $4.8 million in revenue last year. The transaction includes multiple real estate assets tied to indoor cannabis operations and bulk nutrient warehousing.
CEO Scott Cox says the move marks a major step in THC Therapeutics’ roll-up strategy. “This collaboration brings together over 60 years of experience in cannabis operations,” said Cox. “It immediately creates a vertically integrated platform with proven revenue and a strong foundation for national expansion.”
The acquisition gives THC Therapeutics an established presence in both California and Oregon, positioning the company to expand its brands across other state markets and internationally.
THG’s subsidiaries include Jefferson Soul, a legacy grower and extraction brand based in the Emerald Triangle region of Northern California; Kalix, a commercial nutrient company with national and international reach; NPK Industries, a well-known brand among home growers; Harvest Food for Life, which is involved in food security initiatives in West Africa; and two real estate arms, Shasta Properties Management and Blue Sky Investments.
“This isn’t a beginning—it’s a leap forward,” added Cox. “We now have a strong asset base, established operations, and the infrastructure to pursue additional acquisitions and organic growth.”
THG CEO Richard Rowe emphasized the timing, calling this a key moment for consolidation in the cannabis industry. “The market is shifting toward efficiency and proven systems. This partnership provides both,” said Rowe.
With this acquisition, THC Therapeutics aims to become a major player in the regulated cannabis space through strategic consolidation, vertical integration, and scalable growth.
